Lenalidomide After Failure of Hypomethylating Agents in Myelodysplastic Syndrome
Status:
Unknown status
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
This is a Phase II study to evaluate the efficacy of second-line lenalidomide monotherapy for
myelodysplastic syndrome (MDS) patients who failed to hypomethylating agents.